Sevda ÖNDER, Havva ERDEM, Nurten TURHAN HAKTANIR, Mürüvvet AKÇAY ÇELİK, Hilal BALTA

Assessment of BCL-2 expression in actinic keratosis, keratoacanthoma and seborrheic keratosis cases

Aim: One of the main functions of apoptosis is the elimination of cells with damaged DNA, including premalignant cells in skin. Apoptosis is regulated by the balance between antiapoptotic and proapoptotic proteins. The bcl–2 protein has been shown antiapoptotic effect. It protects cell against apoptosis induced by different death-inducing signals.Material and Methods: In this study the authors have analyzed imunohistochemically the expression of bcl-2 protein in the histopathological variants of the precancerous lesion [actinic keratosis (AK) (28 cases) and keratoacanthomas (KA) (12 cases) and seborrheic keratosis (SK) (22 cases) in skin.Results: In cases of AK, bcl-2 expression was confined to basal cell layer, as well as in two cases of thorough epidermis. SK expression of bcl–2 protein was in areas of basaloid proliferation.KA expression of bcl-2 protein was not dome-shaped keratin-filled crater areas but bcl-2 expression was confined of non crater areas.Conclusion: In conclusion, bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes in AK and SK and not support the observation that tumor cells are derived from basal keratinocytes in KA.

PDF

___

1. Kubo Y, Matsudate Y, Fukui N, et al. Molecular tumorigenesis of the skin. J Med Invest 2014;61:7-14.
2. Kwon OS, Hwang EJ, Bae JH, et al. Seborrheic keratosis in the Korean males: causative role of sunlight. Photodermatol Photoimmunol Photomed 2003;19:73-80.
3. Tilli CM, Stavast-Kooy AJ, Ramaekers FC, et al. Bax expression and growth behavior of basal cell carcinomas. J Cutan Pathol 2002;29:79-87.
4. Rossen K, Karabulut Thorup A, Hou-Jensen K, et al. Bax protein is not expressed by basal cell carcinomas. Br J Dermatol 1998;139:472-4.
5. Delehedde M, Cho SH, Sarkiss M, et al. Altered expression of BCL-2 family member proteins in nonmelanoma skin cancer. Cancer 1999;85:1514-22.
6. Cho S, Hahm J-H, Hong YS. Analysis of p53 and bax mutations, loss of heterozygosity, p53 and BCL2 expression and apoptosis in basal cell carcinoma in Korean patients. Br J Dermatol 2001;144:841-8.
7. Rodriguez-Villanueva J, Colome MI, Brisbay S, et al. The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers. Pathol Res Pract1995;191:391-8.
8. Puizina-Ivić N, Sapunar D, Marasović D, et al. An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol 2008;32:61-5.
9. Lu QL, Abel P, Foster CS, et al. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996;27:102-10.
10. Ribeiro D, Narikawa S, Marques ME. Expression of apoptotic and cell proliferation regulatory proteins in keratoacanthomas and squamous cell carcinomas of the skin. Pathol Res Pract 2008;204:97-104.
11. Woo YR, Lim JH, Jeong SW, et al. Analysis of apoptosis-associated molecules erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate. Exp Dermatol 2017;26:1012-7.
12. Hussein MR, Al-Badaiwy ZH, Guirguis MN. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions. J Cutan Pathol. 2004;31:643-51.
13. Polakowska RR, Piacentini M, Bartlett R, et al. Apoptosis in human skin development: morphogenesis, periderm, and stem cells. Dev Dyn 1994;199:176-88.
14. Bircan S, Çandır O, Kapucuoğlu N, et al. p53, BCL-2, bax expression in Basal Cell Carcinomas and Nontumoral Surrounding Skin. Turkish Pathology. 2005;21:044-8.
15. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol 2002;61:20-3.
16. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol. 2007;2:18-20.
17. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007;46:895-904
18. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30.
19. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 2000;42:11-7.
20. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000;42:18-22.
21. Schwartz RA, Bridges TM, Butani AK, et al. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol 2008;22:606-15.
22. Ali FR, Wlodek C, Lear JT. The role of ingenol mebutate in the treatment of actinic keratoses. Dermatol Ther (Heidelb) 2012;2:8.
23. Çayirli M, Köse O, Demiriz M. Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the effectiveness of diclofenac therapy with immunohistochemical analysis. Arch Dermatol Res 2013;305:389-95
24. Stanimirović A, Cupić H, Bosnjak B, et.al. Expression of p53, bcl-2 and growth hormone receptor in atrophic type of actinic keratosis. J Dermatol Sci. 2004;34:49-53.
25. Tomas D, Kruslin B, Cupic H, et al. Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol. 2006;20:51-7.
26. Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology. 2005;47:170-8.
27. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999;199:208-12.
28. Fisher ER, McCoy MM 2nd, Wechsler HL. Analysis of histopathologic and electron microscopic determinants of keratoacanthoma and squamous cell carcinoma. Cancer 1972;29:1387-97.
29. Leblebici C, Pasaoglu E, Kelten C, et al. Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma. Oncol Lett 2017;13:2539-48.
30. Langenbach N, Kroiss MM, Rüschoff J, et al. Assessment of microsatellite instability and loss of heterozygosity in sporadic keratoacanthomas. Arch Dermatol Res 1999;291:1-5.
31. Phillips P, Helm KF. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1993;20:424-8
32. Putti TC, Teh M, Lee YS. Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 2004;17:468-75.
33. Wrone-Smith T, Johnson T, Nelson B, et al. BJ. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995;146:1079-88.
34. Smoller BR, Van de Rijn M, Lebrun D, et al. bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol 1994;131:28-31.
35. Simionescu O, Popescu BO, Costache M, et al. Apoptosis in seborrheic keratoses: an open door to a new dermoscopic score 2012;16:1223-31.
36. Ko CJ, Kim J, Phan J, et al. Bcl-2-positive epidermal dendritic cells in inverted follicular keratoses but not squamous cell carcinomas or seborrheic keratoses. J Cutan Pathol 2006l;33:498-501.
37. Gaballah MA, Ahmed RA. Diagnostic value of CD10 and Bcl2 expression in distinguishing cutaneous basal cell carcinoma from squamous cell carcinoma and seborrheic keratosis. Pathol Res Pract 2015;211:931-8.
38. Ko CJ, Shintaku P, Binder SW. Comparison of benign keratoses using p53, bcl-1, and bcl-2. J Cutan Pathol. 2005;32:356-9.